Expanded access to REGN-EB3 treatment for Ebola
Part of Infections clinical trials.
This trial provides an experimental antibody treatment called REGN-EB3 to people infected with Ebola virus. It aims to treat the infection and potentially improve recovery, and is available through special access in areas with Ebola outbreaks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have tested positive for Ebola and be showing symptoms like fever or weakness.
- You must be in a region where Ebola is common (an endemic area).
- Pregnant women infected with Ebola can receive this treatment.
- Children of any age, including newborns whose mothers have Ebola, may be eligible.
- You cannot be in another clinical trial that is testing the same drug (REGN-EB3).
- You must be willing and able to follow the study plan, including giving your consent (you or a legal representative).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine to prevent Ebola after you have been exposed. If you had close contact with someone who has Ebola in the last 5 days, this study could help you stay healthy.
This trial provides an experimental antibody treatment called ansuvimab to people who have Ebola or have been recently exposed to it. The goal is to help their bodies fight the virus and prevent illness.
This study tests if a booster dose of one of two Ebola vaccines (Ervebo® or Zabdeno®) is safe and works well in people who already got an Ebola vaccine more than 4 months ago. It's especially for people living in the Democratic Republic of Congo (DRC) who may have been vaccinated before and might need a stronger, longer-lasting immune response.
This study looks at whether giving an Ebola treatment (Inmazeb) before the Ebola vaccine (Ervebo) changes the vaccine's effect on healthy people. It helps understand the best timing for these treatments.
This trial is testing a new, faster way to detect Ebola in blood samples. They are using stored blood samples to see if the new test works as well as the standard one.
This study tests a new Ebola vaccine to see if it is safe and how well it works. Healthy volunteers receive the vaccine and are monitored for side effects and immune response.
Hear when a new Ebola Virus Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.